What is Kiromic?
Kiromic BioPharma, Inc. operates as a fully integrated clinical-stage biotherapeutics entity, distinguished by its proprietary DIAMOND AI platform. This artificial intelligence engine is engineered to streamline the discovery, validation, and development of cell and gene therapies. The company's primary focus remains on immuno-oncology, specifically through the development of the ALEXIS platform. This multi-indication allogeneic CAR-T cell therapy utilizes the inherent potency of gamma delta T-cells to address the complexities of solid tumor cancers. By integrating data science with biological target identification, Kiromic aims to significantly reduce the temporal and financial barriers typically associated with cellular therapeutic development, positioning itself as a high-growth player in the biotechnology sector.
How much funding has Kiromic raised?
Kiromic has raised a total of $15M across 1 funding round:
Stock Offering
$15M
Stock Issuance/Offering (2020): $15M, investors not publicly disclosed
Key Investors in Kiromic
Undisclosed Investors
What's next for Kiromic?
With this recent capital allocation, Kiromic is poised to advance its clinical development milestones and expand the utility of its DIAMOND AI platform. The strategic focus will likely center on scaling the ALEXIS platform to meet rigorous regulatory standards while optimizing the manufacturing processes for allogeneic cell therapies. As the company transitions further into its clinical-stage lifecycle, the emphasis will shift toward validating its therapeutic candidates in human trials, thereby de-risking the pipeline for future commercialization. Investors will be monitoring the firm's ability to maintain its competitive edge in the crowded immuno-oncology landscape, particularly as it seeks to demonstrate the efficacy of its gamma delta T-cell approach in treating solid tumors. The integration of AI-driven insights into the clinical workflow remains a critical differentiator for the company's long-term growth trajectory.
See full Kiromic company page
